首页> 外文期刊>Radiation oncology >Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis
【24h】

Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis

机译:扩展场放射治疗的治疗结果及同期化疗对子宫子宫颈癌的疗效淋巴结转移

获取原文
           

摘要

Purpose To review the clinical outcomes of extended-field radiation therapy (EFRT) and to analyze prognostic factors significant for survival in patients receiving EFRT for uterine cervical carcinoma with para-aortic node (PAN) metastasis. Patients and methods We retrospectively reviewed 90 patients with stage IB-IVA cervical cancer and PAN metastasis between 1987 and 2012. Median age was 50 (range, 24–77). Patients received median 70.2 Gy (range, 56–93) to point A and median 50.4 Gy (range, 45–60.4) to PAN over median 69 elapsed days (range, 43–182). Forty-six patients (51.1%) received concurrent chemotherapy. Survival was calculated using the Kaplan–Meier method. We analyzed prognostic factors for overall actuarial survival (OS) and progression-free survival (PFS) using a Cox regression method. Results The median follow-up period for surviving patients was 55 months (range, 3–252). Seventy patients (77.8%) had complete remission. Forty-six patients experienced treatment failure as follows: 11 patients (12.2%) as local recurrence, 19 (21%) as regional recurrence and 33 (36.7%) as distant metastasis. The 5-yr OS and PFS were 62.6% and 43.9%, respectively. Treatment response was the only statistically independent prognostic factors for OS (p= 0.04) and PFS (p Conclusions Our institutional experiences showed that EFRT was an effective treatment for cervical cancer patients with PAN metastasis. The addition of chemotherapy to EFRT seems to have uncertain survival benefit with higher hematologic toxicity.
机译:目的探讨延长场放射治疗(EFRT)的临床结果,并分析患者患者患者对子宫宫颈癌患者的生存率显着的预后因素,具有对主动脉节点(PAN)转移。患者和方法我们回顾性地审查了90例IB-IVA宫颈癌患者,1987年至2012年间PAN转移。中位年龄为50(范围,24-77)。患者收到中位数70.2 GY(范围,56-93)点A和中位数50.4 GY(范围,45-60.4)泛中位数69经过的日子(范围,43-182)。四十六名患者(51.1%)接受同时化疗。使用Kaplan-Meier方法计算生存。我们使用COX回归方法分析了整体致剂存活(OS)和无进展生存(PFS)的预后因素。结果存活患者的中位随访时间为55个月(范围,3-252)。七十名患者(77.8%)完全缓解了缓解。四十六名患者经历了治疗失效,如下:11名患者(12.2%)作为局部复发,19(21%)为区域复发,33(36.7%)为远处转移。 5 yr OS和PFS分别为62.6%和43.9%。治疗反应是OS的唯一统计学独立的预后因素(P = 0.04)和PFS(P结论我们的制度经验表明,EFRT对植物癌患者有效治疗PAN转移患者。向EFRT添加化疗似乎具有不确定的生存血液学毒性更高的益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号